Your browser doesn't support javascript.
loading
Hepatocellular carcinoma: measures to improve the outlook in sub-Saharan Africa.
Spearman, C Wendy; Dusheiko, Geoffrey; Jonas, Eduard; Abdo, Abdelmounem; Afihene, Mary; Cunha, Lina; Desalegn, Hailemichael; Kassianides, Chris; Katsidzira, Leolin; Kramvis, Anna; Lam, Philip; Lesi, Olufunmilayo A; Micah, Eileen A; Musabeyezu, Emmanuel; Ndow, Gibril; Nnabuchi, Chidi V; Ocama, Ponsiano; Okeke, Edith; Rwegasha, John; Shewaye, Abate B; Some, Fatuma F; Tzeuton, Christian; Sonderup, Mark W.
Afiliação
  • Spearman CW; Division of Hepatology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa; Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa. Electronic address: wendy.spearman@uct.ac.za.
  • Dusheiko G; University College London Medical School, London, UK; Kings College Hospital, London, UK.
  • Jonas E; Surgical Gastroenterology Unit, Division of General Surgery, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
  • Abdo A; National Centre for Gastrointestinal and Liver Disease, Ibn Sina Hospital, Alamarat, Khartoum, Sudan.
  • Afihene M; Department of Medicine, College of Health Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
  • Cunha L; Gastroenterology Unit, Maputo Private Hospital, Maputo, Mozambique.
  • Desalegn H; Department of Internal Medicine, St Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia.
  • Kassianides C; Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
  • Katsidzira L; Internal Medicine Unit, Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
  • Kramvis A; Hepatitis Virus Diversity Research Unit, Department of Internal Medicine, School of Clinical Medicine, University of the Witwatersrand, Johannesburg, South Africa.
  • Lam P; Clinique Darné, Curepipe, Mauritius.
  • Lesi OA; Gastroenterology and Hepatology Unit, College of Medicine, University of Lagos, Lagos, Nigeria.
  • Micah EA; Department of Medicine, Komfo Anokye Teaching Hospital, Kumasi, Ghana.
  • Musabeyezu E; Department of Medicine, King Faisal Hospital, Kigali, Rwanda.
  • Ndow G; Disease Control and Elimination Theme, MRC Unit The Gambia at the London School of Tropical Medicine, London, UK; Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
  • Nnabuchi CV; Asokoro District Hospital, Nile University Teaching Hospital, Abuja, Nigeria.
  • Ocama P; School of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.
  • Okeke E; Gastroenterology and Hepatology Unit, Department of Internal Medicine, College of Health Sciences, University of Jos, Jos University Teaching Hospital, Jos, Nigeria.
  • Rwegasha J; Gastroenterology Training Centre, Department of Internal Medicine, Muhimbili National Hospital, Dar Es Salaam, Tanzania.
  • Shewaye AB; Division of Gastroenterology and Hepatology, Department of Internal Medicine, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
  • Some FF; Department of Medicine, School of Medicine, College of Health Sciences, Moi University, Eldoret, Kenya.
  • Tzeuton C; Faculty of Medicine and Pharmaceutical Sciences of Douala, University of Douala, Douala, Cameroon.
  • Sonderup MW; Division of Hepatology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa; Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Lancet Gastroenterol Hepatol ; 7(11): 1036-1048, 2022 11.
Article em En | MEDLINE | ID: mdl-35810766
ABSTRACT
Hepatocellular carcinoma is a leading public health concern in sub-Saharan Africa, and it is most prevalent in young adults (median 45 years [IQR 35-57]). Overall, outcomes are poor, with a median survival of 2·5 months after presentation. Major risk factors for hepatocellular carcinoma are hepatitis B virus (HBV), hepatitis C virus, aflatoxin B1 exposure, and alcohol consumption, with metabolic dysfunction-associated fatty liver disease slowly emerging as a risk factor over the past few years. Crucially, these risk factors are preventable and manageable with effective implementation of the HBV birth-dose vaccination, treatment of chronic viral hepatitis, provision of harm reduction services, and by decreasing aflatoxin B1 exposure and harmful alcohol consumption. Primary prevention is central to the management of hepatocellular carcinoma, especially in poorly resourced environments. Effective screening and surveillance programmes with recall policies need to be implemented, because detection and curative management of hepatocellular carcinoma is possible if it is detected at an early stage, even in countries with minimal resources, with appropriate upskilling of medical personnel. The establishment of centres of excellence with advanced diagnostic and therapeutic capabilities within countries should improve hepatocellular carcinoma outcomes and assist in driving the implementation of much needed systematic data systems focused on hepatocellular carcinoma to establish the accurate burden in sub-Saharan Africa. Such data would support the public health importance of hepatocellular carcinoma and provide a strong basis for advocacy, programme development, resource allocation, and monitoring of progress in reducing mortality.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hepatite C / Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudo: Diagnostic_studies / Etiology_studies Limite: Humans País como assunto: Africa Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hepatite C / Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudo: Diagnostic_studies / Etiology_studies Limite: Humans País como assunto: Africa Idioma: En Ano de publicação: 2022 Tipo de documento: Article